2196 fundamentals
SHANGHAI FOSUN PHARMACEUTICAL GROUP financial statements, including revenue, expenses, profit, and loss
The total revenue of 2196 for the last semiannual is 22.09 B HKD, and it's 2.57% higher compared to the previous semiannual. The net income of H1 24 is 1.33 B HKD.
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
TTM